Please assess the completion status of the following clinical trial:

Trial Title: Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients refractory to BCG therapy;~* Patients with histologically confirmed diagnosis of high grade lesions;~* Diagnosis of high grade lesion must be within 56 days prior to beginning of study treatment;~* Have had all visible papillary lesion(s) resected by TURBT within 56 days prior to beginning of study treatment;~* Available for the whole duration of the study including follow-up (60 months);~* Life expectancy of \> 5 years;~* Patients with an ECOG performance status grade of 2 or less;~* Absence of urothelial carcinoma involving the upper urinary tract or prostatic urethra within 12 months from beginning of study treatment;~* Able to understand and give written informed consent;~* In the investigator's judgment, the patient is able to participate in the study.~Exclusion Criteria:~* Current or previous history of muscle invasive tumors;~* Current or previous history of lymph node or distant metastases from bladder cancer;~* Current systemic cancer therapy;~* Current or prior pelvic external beam radiotherapy;~* Pelvic brachytherapy within 2 years of study entry;~* Prior treatment with MCC;~* Patients with existing urinary tract infection or recurrent severe bacterial cystitis;~* Clinically significant and unexplained elevations of liver or renal function tests;~* White blood cell count below 3 x109/L (3,000/mm3) or platelet count below 100 x 109/L(100,000/mm3);~* Severe cardiovascular disease;~* Women who are pregnant or lactating;~* Congenital or acquired immune deficiency;~* With history of malignancy of any organ system, treated or untreated, within the past 5 years (with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, stage T1 prostate cancer, carcinoma in situ of the cervix or colon polyps);~* Previous investigational treatment within 3 months from beginning of study treatment;~* Patients who cannot hold the instillation for one hour;~* Patients who cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy or biopsy);~* Clinically significant active infections;~* Any medical or psychiatric condition which, in the opinion of the investigator, would preclude the participant from adhering to the protocol or completing the trial per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mycobacterial cell wall-DNA complex (Type: EXPERIMENTAL): Mycobacterial cell wall-DNA complex

Based on this trial design, predict the completion outcome and termination type (if applicable).